Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

Revenue climbs 37% in the quarter driven by Harvoni

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

3Q Revenues: $8.3 billion (+37%)

3Q Earnings: $4.6 billion (+69%)

YTD Revenues: $24.1 billion (+37%)

YTD Earnings: $13.4 billion (+56%)

Comments: Antiviral product sales were $7.7 billion in the quarter, up 40% primarily driven by Harvoni  sales of $3.3 billion, partially offset by a decrease in sales of Sovaldi (-48% to $1.5 billion)  as a result of uptake in Harvoni. Atripla sales were $818 million in the quarter, down 9%. Stribild sales were $511 million, up 56%. Complera sales were $360 million, up 9%. Viread sales were $297 million, up 8%. Letairis sales were $181 million, up 24%. Ranexa sales were up 22% to $161 million. R&D expenses were $743 million in the quarter, up 18%.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters